FIELD: biochemistry.
SUBSTANCE: invention relates to a humanized anti-tau protein or tau-binding fragment thereof, a pharmaceutical composition, an immunoconjugate, as well as a diagnostic reagent thereof. Also disclosed is a nucleic acid molecule encoding said antibody or fragment thereof, as well as a vector and a host cell containing it. Invention also relates to a method of producing a humanised anti-tau protein or tau-binding fragment, providing use of said cell.
EFFECT: invention provides effective prevention or treatment of tautopathy.
28 cl, 46 dwg, 10 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANISED ANTI-TAU ANTIBODIES | 2015 |
|
RU2743152C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES | 2011 |
|
RU2607368C2 |
| ANTI-INTEGRIN ALPHA-2 ANTIBODIES AND USING THEM | 2011 |
|
RU2545401C2 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF INFECTIONS CAUSED BY STAPHYLOCOCCUS AUREUS | 2015 |
|
RU2636780C1 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
| ANTI-LIGAND 1 ANTIBODY OF PROGRAMMED CELL DEATH (PD-L1), ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL APPLICATION | 2016 |
|
RU2727914C2 |
| HUMANIZED ANTIBODIES TO CTLA4 | 2012 |
|
RU2629768C2 |
| ANTI c-Met RECEPTOR PROTEIN ANTIBODIES | 2011 |
|
RU2608644C2 |
